Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2015 Sep;194(3):745-53.
doi: 10.1016/j.juro.2015.05.098. Epub 2015 Jun 9.

Peyronie's Disease: AUA Guideline

Ajay Nehra  1 , Ralph Alterowitz  1 , Daniel J Culkin  1 , Martha M Faraday  1 , Lawrence S Hakim  1 , Joel J Heidelbaugh  1 , Mohit Khera  1 , Erin Kirkby  1 , Kevin T McVary  1 , Martin M Miner  1 , Christian J Nelson  1 , Hossein Sadeghi-Nejad  1 , Allen D Seftel  1 , Alan W Shindel  1 , Arthur L Burnett  1 ; American Urological Association Education and Research, Inc.,
Affiliations
Practice Guideline

Peyronie's Disease: AUA Guideline

Ajay Nehra et al. J Urol. 2015 Sep.

Abstract

Purpose: The purpose of this guideline is to provide a clinical framework for the diagnosis and treatment of Peyronie's disease.

Materials and methods: A systematic review of the literature using the PubMed®, EMBASE® and Cochrane databases (search dates 1/1/1965 to 1/26/15) was conducted to identify peer-reviewed publications relevant to the diagnosis and treatment of PD. The review yielded an evidence base of 303 articles after application of inclusion/exclusion criteria.

Results: The systematic review was used to create guideline statements regarding treatment of PD. When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high quality evidence; high certainty), B (moderate quality evidence; moderate certainty), or C (low quality evidence; low certainty). Evidence-based statements of Strong, Moderate, or Conditional Recommendation were developed based on benefits and risks/burdens to patients. Additional consensus statements related to the diagnosis of PD are provided as Clinical Principles and Expert Opinions due to insufficient published evidence.

Conclusions: There is a continually expanding literature on PD; the Panel notes that this document constitutes a clinical strategy and is not intended to be interpreted rigidly. The most effective approach for a particular patient is best determined by the individual clinician and patient in the context of that patient's history, values, and goals for treatment. As the science relevant to PD evolves and improves, the strategies presented here will be amended to remain consistent with the highest standards of clinical care.

Keywords: fibrosis; penile induration; penis.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURES All panel members completed COI disclosures. Relationships that have expired (more than one year old) since the panel’s initial meeting, are listed. Those marked with (C) indicate that compensation was received; relationships designated by (U) indicate no compensation was received. Consultant/Advisor: Ralph Alterowitz, MEA, The Center for Intimacy After Cancer Therapy Inc. (U); Mohit Khera, MD, Coloplast (C); American Medical Systems (C); Endo Pharmaceuticals (C); Kevin T. McVary, MD, Watson Pharmaceuticals (C), Lilly/ICOS (C), Health Publishing: Arthur L. Burnett II, MD, Urology Times Editorial Council (C); VIVUS (C); Alan W. Shindel, M.D., Endotext.com (C), International Society for Sexual Medicine (C) Leadership Position: Ralph Alterowitz, MEA, The Center for Intimacy After Cancer Therapy Inc. (U); Alan W. Shindel, M.D., Sexual Medicine Society of North America (C) Meeting Participant or Lecturer: Ralph Alterowitz, MEA, The Center for Intimacy After Cancer Therapy Inc. (U); Kevin T. McVary, MD, Watson Pharmaceuticals (C), Lilly/ICOS (C), Lawrence S. Hakim, MD, ENDO Urology (C), Slate/Auxilium (C) Scientific Study or Trial: Arthur L. Burnett II, MD, Acorda Therapeutics (C); Endo Pharmaceuticals (C); Pfizer (C); Auxilium Inc. (C); American Medical Systems (C); Coloplast (C); Astellas (C); Reflexonic LLC (C); VIVUS (C); Kevin T. McVary, MD, Astellas (C), Lilly/ICOS (C), NxThera (U), American Medical Systems (C), Sophris (C); Hossein Sadeghi-Nejad, MD, Endo Pharmaceuticals/Auxilium (C) Other: Kevin T. McVary, MD, Lilly/ICOS, Principal Investigator (C), NIDDK, Principal Investigator (C), Christian J. Nelson, PhD, American Medical Systems (U).

Figures

Figure
Figure
Peyronie’s disease diagnosis and treatment algorithm
See this image and copyright information in PMC

References

    1. Haag SM, Hauck EW, Eickelberg O, et al. Investigation of the antifibrotic effect of IFN-gamma on fibroblasts in a cell culture model of Peyronie’s disease. Eur Urol. 2008;53:425. - PubMed
    1. Mulhall JP. Expanding the paradigm for plaque development in Peyronie’s disease. Int J Impotence Res. 2003;15:S93. - PubMed
    1. Somers KD, Sismour EN, Wright GL, Jr, et al. Isolation and characterization of collagen in Peyronie’s disease. J Urol. 1989;141:629. - PubMed
    1. Somers KD, Dawson DM. Fibrin deposition in Peyronie’s disease plaque. J Urol. 1997;157:311. - PubMed
    1. Nelson CJ, Mulhall JP. Psychological impact of Peyronie’s disease: a Review. J Sex Med. 2013;10:653. - PubMed

Publication types